公开(公告)号：US09226959B2

公开(公告)日：2016-01-05

申请号：US12672442

申请日：2009-01-28

申请人： Thomas Kramps ,  Söhnke Voss ,  Jochen Probst ,  Ingmar Hoerr

发明人： Thomas Kramps ,  Söhnke Voss ,  Jochen Probst ,  Ingmar Hoerr

IPC分类号： C07H21/02 ,  A61K39/00 ,  A61K39/39 ,  A61P37/04 ,  C07H21/00 ,  C12N15/117

CPC分类号： A61K39/39 ,  A61K2039/53 ,  A61K2039/55561 ,  A61K2039/572 ,  C07H21/00 ,  C12N15/117 ,  C12N2310/17 ,  C12N2310/314 ,  C12N2310/315 ,  C12N2320/31 ,  Y02A50/491

摘要： The present invention relates to nucleic acids of the general formula (I): (NuGlXmGnNv)a and derivatives thereof as an immunostimulating agent/adjuvant and to compositions containing same, optionally comprising an additional adjuvant. The present invention furthermore relates to a pharmaceutical composition or to a vaccine, each containing nucleic acids of formula (I) above and/or derivatives thereof as an immunostimulating agent, and optionally at least one additional pharmaceutically active component, e.g. an antigenic agent. The present invention relates likewise to the use of the pharmaceutical composition or of the vaccine for the treatment of cancer diseases, infectious diseases, allergies and autoimmune diseases etc. Likewise, the present invention includes the use of nucleic acids of the general formula (I): (NuGlXmGnNv)a and/or derivatives thereof for the preparation of a pharmaceutical composition for the treatment of such diseases.

摘要翻译： 本发明涉及通式（I）的核酸：（NuG1XmGnNv）a及其衍生物作为免疫刺激剂/佐剂和含有其的组合物，任选地包含另外的佐剂。 本发明还涉及药物组合物或疫苗，其各自含有上述式（I）核酸和/或其衍生物作为免疫刺激剂，以及任选的至少一种另外的药物活性成分，例如， 抗原剂。 本发明同样涉及药物组合物或疫苗用于治疗癌症疾病，感染性疾病，过敏症和自身免疫疾病等的用途。同样地，本发明包括通式（I）的核酸， ：（NuGlXmGnNv）a和/或其衍生物，用于制备用于治疗这些疾病的药物组合物。

公开(公告)号：US20120021043A1

公开(公告)日：2012-01-26

申请号：US12672442

申请日：2009-01-28

申请人： Thomas Kramps ,  Sohnke Voss ,  Jochen Probst ,  Ingmar Hoerr

发明人： Thomas Kramps ,  Sohnke Voss ,  Jochen Probst ,  Ingmar Hoerr

IPC分类号： A61K39/39 ,  A61K9/127 ,  A61K38/20 ,  A61P37/04 ,  A61K9/14 ,  A61K39/395 ,  A61K39/00 ,  A61P35/00 ,  C07H21/02 ,  A61K38/21

CPC分类号： A61K39/39 ,  A61K2039/53 ,  A61K2039/55561 ,  A61K2039/572 ,  C07H21/00 ,  C12N15/117 ,  C12N2310/17 ,  C12N2310/314 ,  C12N2310/315 ,  C12N2320/31 ,  Y02A50/491

摘要： The present invention relates to nucleic acids of the general formula (I): (NuGlXmGnNv)a and derivatives thereof as an immunostimulating agent/adjuvant and to compositions containing same, optionally comprising an additional adjuvant. The present invention furthermore relates to a pharmaceutical composition or to a vaccine, each containing nucleic acids of formula (I) above and/or derivatives thereof as an immunostimulating agent, and optionally at least one additional pharmaceutically active component, e.g. an antigenic agent. The present invention relates likewise to the use of the pharmaceutical composition or of the vaccine for the treatment of cancer diseases, infectious diseases, allergies and autoimmune diseases etc. Likewise, the present invention includes the use of nucleic acids of the general formula (I): (NuGlXmGnNv)a and/or derivatives thereof for the preparation of a pharmaceutical composition for the treatment of such diseases.

摘要翻译： 本发明涉及通式（I）的核酸：（NuG1XmGnNv）a及其衍生物作为免疫刺激剂/佐剂和含有其的组合物，任选地包含另外的佐剂。 本发明还涉及药物组合物或疫苗，其各自含有上述式（I）核酸和/或其衍生物作为免疫刺激剂，以及任选的至少一种另外的药物活性成分，例如， 抗原剂。 本发明同样涉及药物组合物或疫苗用于治疗癌症疾病，感染性疾病，过敏症和自身免疫疾病等的用途。同样地，本发明包括通式（I）的核酸， ：（NuGlXmGnNv）a和/或其衍生物，用于制备用于治疗这些疾病的药物组合物。

公开(公告)号：US20130121988A1

公开(公告)日：2013-05-16

申请号：US13492787

申请日：2012-06-08

申请人： Ingmar Hoerr ,  Jochen Probst ,  Thomas Ketterer ,  Birgit Scheel

发明人： Ingmar Hoerr ,  Jochen Probst ,  Thomas Ketterer ,  Birgit Scheel

IPC分类号： A61K39/39

CPC分类号： A61K39/39 ,  A61K2039/55561 ,  C07H21/02 ,  C12N15/117 ,  C12N2310/17 ,  C12N2310/3515

摘要： The present invention relates to a nucleic acid of the general formula (I): GlXmGn, which may be modified by a lipid. The invention relates further to a pharmaceutical composition containing an immune-stimulating agent according to the invention in combination with a pharmaceutically active carrier/vehicle (and, optionally, further auxiliary substances, additives and/or further adjuvants). The present invention can relate to a vaccine, which corresponds to a pharmaceutical composition of the invention, wherein the pharmaceutically active component induces a specific immune response (e.g. an antigen). The present invention can relate to the use of a nucleic acid of the invention or a pharmaceutical composition according to the invention for the treatment of infectious diseases, autoimmune disease, allergies or cancer diseases.

摘要翻译： 本发明涉及通式（I）的核酸：GlXmGn，其可以被脂质修饰。 本发明进一步涉及含有根据本发明的免疫刺激剂与药物活性载体/载体（和任选的其它辅助物质，添加剂和/或其它辅助剂）组合的药物组合物。 本发明可以涉及对应于本发明的药物组合物的疫苗，其中药物活性成分诱导特异性免疫应答（例如抗原）。 本发明可以涉及本发明的核酸或根据本发明的药物组合物用于治疗感染性疾病，自身免疫性疾病，过敏或癌症疾病的用途。

公开(公告)号：US20100189729A1

公开(公告)日：2010-07-29

申请号：US12522214

申请日：2008-01-08

申请人： Ingmar Hoerr ,  Jochen Probst ,  Steve Pascolo

发明人： Ingmar Hoerr ,  Jochen Probst ,  Steve Pascolo

IPC分类号： A61K39/00 ,  C07H21/02 ,  C12P19/34 ,  A61P37/04

CPC分类号： C07K16/2887 ,  A61K2039/53 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/56 ,  Y02A50/388 ,  Y02A50/41 ,  Y02A50/412

摘要： The present application describes an antibody-coding, non-modified or modified RNA and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, auto-immune diseases, virus diseases and monogenetic diseases, e.g. also in gene therapy. The present invention furthermore describes an in vitro transcription method, in vitro methods for expression of this antibody using the RNA according to the invention and an in vivo method.

摘要翻译： 本申请描述了抗体编码，未修饰或修饰的RNA及其用于表达该抗体的用途，用于制备药物组合物，特别是被动疫苗，用于治疗肿瘤和癌症疾病，心血管疾病， 传染病，自身免疫疾病，病毒性疾病和单一疾病，例如 也在基因治疗。 本发明还描述了体外转录方法，使用本发明的RNA和体内方法来表达该抗体的体外方法。

公开(公告)号：US20100305196A1

公开(公告)日：2010-12-02

申请号：US12682187

申请日：2008-10-08

申请人： Jochen Probst ,  Ingmar Hoerr ,  Thomas Lander

发明人： Jochen Probst ,  Ingmar Hoerr ,  Thomas Lander

IPC分类号： A61K31/711 ,  C07H21/02 ,  A61P35/00 ,  A61P37/04

CPC分类号： A61K39/0011 ,  A61K39/00 ,  A61K39/39 ,  A61K2039/53 ,  A61K2039/55516 ,  A61K2039/572 ,  A61K2039/575 ,  A61K2039/70

摘要： The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably an mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal wherein the antigens are selected from the group consisting of PSA (Prostate-Specific Antigen), PSMA (Prostate-Specific Membrane Antigen), PSCA (Prostate Stem Cell Antigen), and STEAP (Six Transmembrane Epithelial Antigen of the Prostate). The invention furthermore relates to a vaccine comprising said active (immunostimulatory) composition, and to the use of said active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of prostate cancer (PCa), preferably of neoadjuvant and/or hormone-refractory prostate cancers, and diseases or disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and/or the vaccine.

摘要翻译： 本发明涉及包含至少一种RNA（优选mRNA）的活性（免疫刺激性）组合物，其编码至少两种（优选不同的）能够在哺乳动物中引发（适应性）免疫应答的抗原，其中所述抗原选自组 由PSA（前列腺特异性抗原），PSMA（前列腺特异性膜抗原），PSCA（前列腺干细胞抗原）和STEAP（前列腺的六跨膜上皮抗原）组成。 本发明还涉及包含所述活性（免疫刺激）组合物的疫苗，以及所述活性（免疫刺激性）组合物（用于制备疫苗）和/或用于引发（适应性）免疫应答的疫苗的用途 治疗前列腺癌（PCa），优选新辅助和/或激素难治性前列腺癌，以及与之相关的疾病或病症。 最后，本发明涉及试剂盒，特别涉及含有活性（免疫刺激）组合物和/或疫苗的试剂盒。

公开(公告)号：US20100291156A1

公开(公告)日：2010-11-18

申请号：US12682213

申请日：2008-10-08

申请人： Marijke Barner ,  Jochen Probst ,  Thomas Lander ,  Ingmar Hoerr

发明人： Marijke Barner ,  Jochen Probst ,  Thomas Lander ,  Ingmar Hoerr

IPC分类号： A61K39/00 ,  A61P37/04 ,  A61P35/00 ,  C07H21/02

CPC分类号： A61K39/0011 ,  A61K2039/53 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/575 ,  A61K2039/70

摘要： The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably a mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal. The invention furthermore relates to a vaccine comprising said active (immunostimulatory) composition, and to the use of said active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, particularly of non-small cell lung cancers (NSCLC), preferably selected from the three main sub-types squamous cell lung carcinoma, adenocarcinoma and large cell lung carcinoma, or of disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and/or the vaccine.

摘要翻译： 本发明涉及包含至少一种编码至少两种（优选不同的）抗原的RNA，优选mRNA的活性（免疫刺激）组合物，其能够在哺乳动物中引发（适应性的）免疫应答。 本发明还涉及包含所述活性（免疫刺激）组合物的疫苗，以及所述活性（免疫刺激性）组合物（用于制备疫苗）和/或用于引发（适应性）免疫应答的疫苗的用途 治疗肺癌，特别是非小细胞肺癌（NSCLC），优选选自三种主要亚型鳞状细胞肺癌，腺癌和大细胞肺癌，或与其相关的疾病。 最后，本发明涉及试剂盒，特别涉及含有活性（免疫刺激）组合物和/或疫苗的试剂盒。

公开(公告)号：US11421038B2

公开(公告)日：2022-08-23

申请号：US12522214

申请日：2008-01-08

申请人： Ingmar Hoerr ,  Jochen Probst ,  Steve Pascolo

发明人： Ingmar Hoerr ,  Jochen Probst ,  Steve Pascolo

IPC分类号： A61K39/00 ,  C07K16/28 ,  C07K16/32

摘要： The present application describes an antibody-coding, non-modified or modified RNA and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, auto-immune diseases, virus diseases and monogenetic diseases, e.g. also in gene therapy. The present invention furthermore describes an in vitro transcription method, in vitro methods for expression of this antibody using the RNA according to the invention and an in vivo method.

公开(公告)号：US10441653B2

公开(公告)日：2019-10-15

申请号：US13492787

申请日：2012-06-08

申请人： Ingmar Hoerr ,  Jochen Probst ,  Thomas Ketterer ,  Birgit Scheel

发明人： Ingmar Hoerr ,  Jochen Probst ,  Thomas Ketterer ,  Birgit Scheel

IPC分类号： A61K39/39 ,  C07H21/02 ,  C12N15/117 ,  A61K39/00

摘要： The present invention relates to a nucleic acid of the general formula (I): GIXmGn, which may be modified by a lipid. The invention relates further to a pharmaceutical composition containing an immune-stimulating agent according to the invention in combination with a pharmaceutically active carrier/vehicle (and, optionally, further auxiliary substances, additives and/or further adjuvants). The present invention can relate to a vaccine, which corresponds to a pharmaceutical composition of the invention, wherein the pharmaceutically active component induces a specific immune response (e.g. an antigen). The present invention can relate to the use of a nucleic acid of the invention or a pharmaceutical composition according to the invention for the treatment of infectious diseases, autoimmune disease, allergies or cancer diseases.

公开(公告)号：US20090324584A1

公开(公告)日：2009-12-31

申请号：US12375178

申请日：2007-07-31

申请人： Ingmar Hoerr ,  Jochen Probst ,  Thomas Ketterer ,  Birgit Scheel

发明人： Ingmar Hoerr ,  Jochen Probst ,  Thomas Ketterer ,  Birgit Scheel

IPC分类号： A61K39/395 ,  C07H21/00 ,  C07H21/02 ,  C07H21/04 ,  A61K31/7088 ,  A61K38/00 ,  A61K35/12 ,  A61K39/00

CPC分类号： A61K39/39 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/55572 ,  C07H21/02 ,  C12N15/117 ,  C12N2310/17 ,  C12N2310/3515 ,  Y02A50/412 ,  Y02A50/487

摘要： The present invention relates to a nucleic acid of the general formula (I): GlXmGn, or (II): ClXmCn, which may be modified by a lipid. The nucleic acid of the invention acts as an immune-stimulating agent inducing the innate immune response. The invention relates further to a pharmaceutical composition (in a first embodiment), each containing an immune-stimulating agent according to the invention in combination with a pharmaceutically active carrier/vehicle (and, optionally, further auxiliary substances, additives and/or further adjuvants). In another embodiment, the inventive nucleic acid is combined with at least one pharmaceutically active component, a pharmaceutically acceptable carrier/vehicle (and, optionally, further auxiliary substances, additives and/or further adjuvants). Accordingly, the present invention is directed to a vaccine, which corresponds to a pharmaceutical composition of the invention (second embodiment), wherein the pharmaceutically active component induces a specific immune response (e.g. an antigen). The present invention relates likewise to the use of a nucleic acid of the invention or a pharmaceutical composition according to the invention for the treatment of infectious diseases, autoimmune diseases, allergies or cancer diseases.

摘要翻译： 本发明涉及通式（I）的核酸：GlXmGn或（II）：ClXmCn，其可以被脂质修饰。 本发明的核酸作为诱导先天免疫应答的免疫刺激剂起作用。 本发明进一步涉及药物组合物（在第一个实施方案中），每个药物组合物含有根据本发明的免疫刺激剂与药物活性载体/载体（以及任选的其它辅助物质，添加剂和/或其它佐剂）的组合 ）。 在另一个实施方案中，将本发明的核酸与至少一种药学活性成分，药学上可接受的载体/载体（和任选的其它辅助物质，添加剂和/或其它佐剂）组合。 因此，本发明涉及对应于本发明的药物组合物（第二实施方案）的疫苗，其中药物活性成分诱导特异性免疫应答（例如抗原）。 本发明同样涉及本发明的核酸或根据本发明的药物组合物用于治疗感染性疾病，自身免疫性疾病，过敏或癌症疾病的用途。

公开(公告)号：US09234013B2

公开(公告)日：2016-01-12

申请号：US13321474

申请日：2011-08-12

申请人： Andreas Thess ,  Thomas Schlake ,  Jochen Probst

发明人： Andreas Thess ,  Thomas Schlake ,  Jochen Probst

IPC分类号： A61K48/00 ,  C07K14/435 ,  C12N15/67 ,  A61K38/02 ,  A61K38/03 ,  A61K38/04 ,  A61K38/10 ,  A61K38/16 ,  C07H21/04

CPC分类号： A61K48/0066 ,  A61K39/0011 ,  A61K2039/53 ,  A61K2039/575 ,  C07K14/435 ,  C12N15/67

摘要： The present application describes a coding nucleic acid sequence, particularly a messenger RNA (mRNA), comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal and the use thereof for increasing the expression of an encoded protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine e.g. for the use in the treatment of tumors and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases or genetic diseases, or in gene therapy. The present invention further describes an in vitro transcription method, in vitro methods for increasing the expression of a protein using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal and an ex vivo and in vivo method.

摘要翻译： 本申请描述了编码核酸序列，特别是信使RNA（mRNA），其包含或编码组蛋白茎环和聚（A）序列或多聚腺苷酸化信号，以及其用于增加编码蛋白质的表达的用途 。 它还公开了其用于制备药物组合物，特别是疫苗的制剂。 用于治疗肿瘤和癌症疾病，心血管疾病，感染性疾病，自身免疫性疾病或遗传性疾病，或用于基因治疗。 本发明进一步描述体外转录方法，使用包含或编码组蛋白茎环和聚（A）序列或多聚腺苷酸化信号的核酸增加蛋白质表达的体外转录方法，以及离体和/ 体内法。